Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Acquires 10,000 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The stock was bought at an average price of $4.76 per share, with a total value of $47,600.00. Following the transaction, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. This represents a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Tuesday, February 25th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The stock was bought at an average price of $4.46 per share, with a total value of $44,600.00.

Vanda Pharmaceuticals Trading Up 1.3 %

VNDA stock opened at $4.76 on Friday. Vanda Pharmaceuticals Inc. has a one year low of $3.71 and a one year high of $6.75. The firm has a market capitalization of $277.58 million, a PE ratio of -14.88 and a beta of 0.74. The firm has a 50-day moving average of $4.59 and a two-hundred day moving average of $4.80.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its holdings in shares of Vanda Pharmaceuticals by 1,184.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 57,393 shares during the period. FMR LLC increased its holdings in Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 30,802 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Vanda Pharmaceuticals in the third quarter worth approximately $864,000. GSA Capital Partners LLP acquired a new position in Vanda Pharmaceuticals in the third quarter worth approximately $143,000. Finally, Barclays PLC increased its holdings in Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after buying an additional 86,677 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on VNDA shares. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright upped their price target on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.